指南与共识呼吸衰竭与机械通气消化、代谢与肾脏急症重症综合管理与镇静镇痛

COVID-19新变异株(XBB.1.5与XBB.1.16「Arcturus」):高度关注问题综述、不同高峰比较及一般人群与高危人群预防、疫苗接种和治疗专家建议的系统综述

New variants of COVID-19 (XBB.1.5 and XBB.1.16, the "Arcturus"): A review of highly questioned concerns, a brief comparison between different peaks in the COVID-19 pandemic, with a focused systematic review on expert recommendations for prevention, vaccination, and treatment measures in the general population and at-risk groups.
指南 / 共识 · Immun Inflamm Dis · 2024-01-01
一句话结论指南推荐继续个人防护措施、第三和第四剂加强针及二价mRNA疫苗加强针;共识抗病毒治疗为奈玛特韦联合利托那韦,暴露前预防共识为替沙格韦单抗联合西加韦单抗。

本文围绕当前Omicron高峰(主要为XBB.1.5和XBB.1.16亚变异株)提出五个高度关注问题,检索四个主要在线数据库回答前四个问题,并以「Omicron」「指南」「推荐」为关键词对文献进行系统综述回答最后一个问题,共纳入31篇文章。当前Omicron波的主要症状包括特征性高热、咳嗽、结膜炎(伴眼痒)、咽痛、流涕、鼻塞、乏力、身痛和头痛,症状中位潜伏期较此前高峰缩短;针对COVID的疫苗接种对新亚变异株仍可认为有效。指南推荐继续个人防护措施、第三和第四剂加强针以及二价mRNA疫苗加强针;共识抗病毒治疗为奈玛特韦联合利托那韦,暴露前预防共识为替沙格韦单抗联合西加韦单抗。作者希望本文提高对COVID持续存在及降低风险方式的认识,尤其针对高危人群。

要点

  • 当前Omicron波主要症状包括特征性高热、咳嗽、结膜炎(伴眼痒)、咽痛、流涕、鼻塞、乏力、身痛和头痛。
  • 当前Omicron波症状中位潜伏期较此前高峰缩短。
  • 针对COVID的疫苗接种对新亚变异株仍可认为有效。
  • 指南推荐继续个人防护措施、第三和第四剂加强针及二价mRNA疫苗加强针。
  • 共识抗病毒治疗为奈玛特韦联合利托那韦,暴露前预防共识为替沙格韦单抗联合西加韦单抗。

适用人群与场景

  • 一般人群与高危人群(at-risk groups)
  • 当前Omicron高峰(主要为XBB.1.5和XBB.1.16亚变异株)

处置流程与药物剂量

  • 指南推荐继续个人防护措施。
  • 指南推荐第三和第四剂加强针。
  • 指南推荐二价mRNA疫苗加强针。
  • 共识抗病毒治疗为奈玛特韦联合利托那韦联合治疗。
  • 暴露前预防共识为替沙格韦单抗联合西加韦单抗组合。

研究设计与关键结果

  • 本综述围绕当前Omicron高峰提出五个高度关注问题,检索四个主要在线数据库回答前四个问题,并以「Omicron」「指南」「推荐」为关键词对文献进行系统综述回答最后一个问题。
  • 共纳入31篇文章。
  • 当前Omicron波的主要症状包括特征性高热、咳嗽、结膜炎(伴眼痒)、咽痛、流涕、鼻塞、乏力、身痛和头痛。
  • 当前Omicron波症状中位潜伏期较此前高峰缩短。
  • 针对COVID的疫苗接种对新亚变异株仍可认为有效。

证据类型、等级与局限

  • 证据类型:综述及系统综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 指南推荐继续个人防护措施、第三和第四剂加强针及二价mRNA疫苗加强针。
  • 共识抗病毒治疗为奈玛特韦联合利托那韦联合治疗。
  • 暴露前预防共识为替沙格韦单抗联合西加韦单抗组合。
  • 作者希望本文提高对COVID持续存在及降低风险方式的认识,尤其针对高危人群。

指南或共识出处

  • 本文为综述,引用指南与推荐文献,原文未列出具体指南名称与发布机构。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: The COVID-19 pandemic has taken many forms and continues to evolve, now around the Omicron wave, raising concerns over the globe. With COVID-19 being declared no longer a "public health emergency of international concern (PHEIC)," the COVID pandemic is still far from over, as new Omicron subvariants of interest and concern have risen since January of 2023. Mainly with the XBB.1.5 and XBB.1.16 subvariants, the pandemic is still very much "alive" and "breathing."

METHODS: This review consists of five highly concerning questions about the current state of the COVID Omicron peak. We searched four main online databases to answer the first four questions. For the last one, we performed a systematic review of the literature, with keywords "Omicron," "Guidelines," and "Recommendations."

RESULTS: A total of 31 articles were included. The main symptoms of the current Omicron wave include a characteristically high fever, coughing, conjunctivitis (with itching eyes), sore throat, runny nose, congestion, fatigue, body ache, and headache. The median incubation period of the symptoms is shorter than the previous peaks. Vaccination against COVID can still be considered effective for the new subvariants.

CONCLUSION: Guidelines recommend continuation of personal protective measures, third and fourth dose boosters, along with administration of bivalent messenger RNA vaccine boosters. The consensus antiviral treatment is combination therapy using Nirmatrelvir and Ritonavir, and the consensus for pre-exposure prophylaxis is Tixagevimab and Cilgavimab combination. We hope the present paper raises awareness for the continuing presence of COVID and ways to lower the risks, especially for at-risk groups.

来源:Immun Inflamm Dis,查看原文。版权归原作者所有。

参考来源

  1. Pourriyahi H, Hajizadeh N, Khosravi M, et al. New variants of COVID-19 (XBB.1.5 and XBB.1.16, the "Arcturus"): A review of highly questioned concerns, a brief comparison between different peaks in the COVID-19 pandemic, with a focused systematic review on expert recommendations for prevention, vaccination, and treatment measures in the general population and at-risk groups. Immun Inflamm Dis. 2024. PMID: 38938013. doi:10.1002/iid3.1323

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。